导师介绍

分子医学博士生导师尹东介绍

个人简介:

  研究员,博士生导师。中山大学孙逸仙纪念医院医学研究中心主任。以医研中心为实验平台,积极协助医院获得了广东省恶性肿瘤表观遗传与基因调控重点实验室,并担任重点实验室专职副主任。建成和完善了DNA测序分析平台、蛋白质检测平台、细胞培养观察平台、细胞流式分析分选平台。把医研中心建成一个高水平综合性的医学科研基地,为在读研究生及科研人员提供良好的实验条件和技术平台。同时,还协助组建了临床分子诊断中心,开展临床分子诊断服务项目。将基础研究和临床应用有机的结合在一起,以推进科研成果向临床转化。

  一直从事分子肿瘤学研究,曾以博士后、助教授和副教授在美国加州大学洛杉矶分校医学院西达赛奈医疗中心学习和工作十多年。先后在Nucleic Acids Research、Hepatology、EMBO Report、Cancer Research、Clinical Cancer Research、Oncogene、Molecular Cancer Research、International Journal of Cancer等国际知名的肿瘤学学术期刊上发表SCI研究论文50余篇,其中30多篇第一作者和/或通信作者论文。主持的项目有:国家自然科学基金国际合作重点和面上项目6项、广东省协同创新与平台建设国际合作领域和创新团队项目2项、广州市健康医疗协同创新重大专项等多项。

 
个人简历:

现任

医学研究中心 主任

广东省恶性肿瘤表观遗传与基因调控重点实验室 常务副主任

广东普通高校恶性肿瘤基因调控与靶向治疗重点实验室 常务副主任

广州市恶性肿瘤基因调控与转化研究重点实验室 常务副主任

 

社会兼职:

广东省医学会:医学实验室建设与管理学分会 副主委

广东省医学会:精准医学与分子诊断学 常务委员

广东省抗癌协会:肿瘤转移专业委员会 委员

美国抗癌协会:   American Association for Cancer Research  (AACR) 会员

国家自然科学基金委:二审专家

 
教学情况:

博士生导师。招生专业:分子医学。

 

科研工作:

主要研究方向

1. 肿瘤基因组学和肿瘤分子遗传学

2. 癌症相关基因及其表达调控

3. 抗肿瘤小分子药物机理

4. 肿瘤表观遗传学

5. 肿瘤分子分型与分子诊断

 

著作、论文、成果:

发表论著 

(#第一作者,*通讯作者)

1. Liao, J.Y#*., Yang, B., Zhang, Y.C., Wang, X.J., Ye, Y., Peng, J.W., Yang, Z.Z., He, J.H., Zhang, Y., Hu, K. Lin, D.C.* and Yin Dong*. (2019) EuRBPDB: a comprehensive resource for annotation, functional and oncological investigation of eukaryotic RNA binding proteins (RBPs). Nucleic acids research. 

2. YT Li, Nan Zhou, Wei-xi Deng, Xue-zhen Zeng, Jian-you Liao*, Dong Yin*. CIRDES: an efficient genome-wide method for in vivo RNA-RNA interactome analysis[J]. Analyst, 2019.8 (https:// doi.org/10.1039/ C9AN01054H), Cover article.

3. Hu K#, Wu W#, Li Y#, Lin L, Chen D, Yan H, Xiao X, Chen H, Chen Z, Zhang Y, Xu S, Guo Y, Koeffler HP, Song E*, Yin Dong*. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.. 2019 May;20(5). PubMed PMID: 30940648; EMBO Report.

4. Lehang Lin#, Moli Huang#, Xianping Shi#, Anand Mayakonda, Kaishun Hu, Yan-Yi Jiang, Xiao Guo, Li Chen, Brendan Pang, Ngan Doan, Jonathan W. Said, Jianjun Xie, Sigal Gery, Xu Cheng, Zhaoyu Lin, Jinsong Li, Benjamin P. Berman, Dong Yin*, De-Chen Lin*, H. Phillip Koeffler. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1. 2018. Nucleic Acids Research.

5. De-Chen Lin#*, Anand Mayakonda, Huy Q Dinh, Pinbo Huang, Lehang Lin, Xiaoping Liu, Ling-Wen Ding, jie wang, Benjamin Berman, Erwei Song, Dong Yin* and H. Phillip Koeffler. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. 2017. Cancer Research. 

6. Huang P#, Zhuang B#, Zhang H#, Yan H, Xiao Z, Li W, Zhang J, Tang Q, Hu K, Koeffler HP, Wang J*, Dong Yin*. Hepatitis B virus X protein (HBx) is responsible for resistance to targeted therapies in hepatocellular carcinoma: ex vivo culture evidence. 2015 Oct 1;21(19):4420-30. Clin Cancer Research.

7. De-Chen Lin#*, Liang Xu, Ye Chen, Haiyan Yan, Masaharu Hazawa, Ngan Doan, Jonathan W. Said, Ling-Wen Ding, Li-Zhen Liu, Henry Yang, Shizhu Yu, Michael Kahn, Dong Yin*, H. Phillip Koeffler. Genomic and functional analysis of the E3 ligase PARK2 in glioma. 2015, 75(9):1815-27. Cancer Research. 

8. Dong Yin#*, Seishi Ogawa, Norihiko Kawamata, Amanda Leiter, Michelle Ham, Dong Li, Ngan B Doan, Jonathan W. Said, Keith L. Black, H. Phillip Koeffler (2013). miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. 2013 Feb 28;32(9):1155-63. Oncogene.

9. Yin Z#, Liu C, Chen Y, Bai Y, Shang C, Yin R, Dong Yin*, Wang J*. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or Delayed? 2013 Jun;57(6):2346-57. Hepatology 

10. Dong Yin#*, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said,JW, Black KL, Koeffler HP. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. 2010. 127(10):2257-67. International Journal of Cancer

11. Dong Yin#*, Naoki Wakimoto, Hongtao Xing, Daning Lu, Thien Huynh, Xiao Wang, Keith L. Black, H. Phillip Koeffler (2008). Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. 15;123(6):1364-75. International Journal of Cancer. 

12. Dong Yin#*, John M. Ong, Jinwei Hu, Julian C. Desmond, Norihiko Kawamata, Bindu M Konda, Keith L. Black, H. Phillip Koeffler. (2007)SuberoylanilideHydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Effects on Gene Expression and Growth of Glioma Cells in vitro and vivo. 13(3):1045-1052. Clinical Cancer Research. 

13. Dong Yin#*, Dong Xie, Sakura Sakajiri, Carl W. Miller, Hui Zhu, Miriam L. Popoviciu, Johathan W. Said, Keith L Black, and H. Phillip Koeffler. (2006) DLK1: Increased expression in gliomas and associated with oncogenic activities. 25:1852-1861. Oncogene

14. Dong Yin#*, Hong Zhou, Kumagai Takashi, Gentao Liu, John M. Ong2 Keith L. Black, and H. Phillip Koeffler. (2005) Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastomamultiforme (GBM). 24: 344–354. Oncogene.

15. Dong Yin#*, Dong Xie, Wolf-Karsten Hofmann, Carl W. Miller, Keith L Black, H. Phillip Koeffler. (2002) Methylation, Expression, and Mutation Analysis of the Cell Cycle Control Genes in Human Brain Tumors. 21:8372-8378. Oncogene.

 

 

更新时间:2019年12月11日

相关文章

  • 中山大学孙逸仙纪念医院研究生科

    电话:020-81332468,传真:020-81332608

    邮箱:graduate2@163.com

    地址:广州市沿江西路107号中山大学孙逸仙纪念医院中山楼703室

    办公时间:周一到周五 上午8:00-12:00,下午2:30-5:30